34 related articles for article (PubMed ID: 38604797)
21. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100mg/m
Solignac J; Farnault L; Robert T; Fanciullino R; Choquet S; Brunet P; Venton G; Bobot M
Nefrologia (Engl Ed); 2022; 42(2):130-134. PubMed ID: 36153909
[TBL] [Abstract][Full Text] [Related]
23. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
[TBL] [Abstract][Full Text] [Related]
24. Primary central nervous system lymphoma.
Schaff LR; Grommes C
Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
[TBL] [Abstract][Full Text] [Related]
25. Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL.
Terao T; Tsushima T; Ikeda D; Fukumoto A; Kamura Y; Kuzume A; Tabata R; Miura D; Narita K; Takeuchi M; Matsue K
Leuk Lymphoma; 2022 Dec; 63(14):3394-3401. PubMed ID: 36111741
[TBL] [Abstract][Full Text] [Related]
26. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
Ferreri AJ; Reni M; Villa E
Ann Oncol; 2000 Aug; 11(8):927-37. PubMed ID: 11038028
[TBL] [Abstract][Full Text] [Related]
29. Central Nervous System Lymphoma: Novel Therapies.
Fortin Ensign SP; Gathers D; Wiedmeier JE; Mrugala MM
Curr Treat Options Oncol; 2022 Jan; 23(1):117-136. PubMed ID: 35182298
[TBL] [Abstract][Full Text] [Related]
30. [Clinical study of 15 cases of primary non-immunodeficient central nervous system lymphoma in children].
Gao HX; Zhang NN; Zhou CJ; Jin L; Yang J; Huang S; Zhang M; Li N; Zhang YH; Duan YL
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):190-194. PubMed ID: 38604797
[TBL] [Abstract][Full Text] [Related]
31. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
32. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
[TBL] [Abstract][Full Text] [Related]
33. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
34. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]